2018 Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) Focused Update of the Guidelines for the use of Antiplatelet Therapy

Publication date: Available online 19 December 2017 Source:Canadian Journal of Cardiology Author(s): Shamir R. Mehta, Kevin R. Bainey, Warren J. Cantor, Marie Lordkipanidzé, Guillaume Marquis-Gravel, Simon D. Robinson, Matthew Sibbald, Derek Y. So, Graham C. Wong, Joseph G. Abunassar, Margaret L. Ackman, Alan D. Bell, Raymond Cartier, James D. Douketis, Patrick R. Lawler, Michael S. McMurtry, Jacob A. Udell, Sean van Diepen, Subodh Verma, G.B. John Mancini, John A. Cairns, Jean-François Tanguay, Paul W. Armstrong, Akshay Bagai, Claudia Bucci, Jean-Pierre Déry, Jean Diodati, Jocelyn Dupuis, David Fitchett, Michael P. Love, Robert Welsh Antiplatelet therapy (APT) has become an important tool in the treatment and prevention of atherosclerotic events, particularly those associated with coronary artery disease. A large evidence base has evolved regarding the relationship between APT prescription in various clinical contexts and risk/benefit relationships. The Guidelines Committee of the Canadian Cardiovascular Society and Canadian Association of Interventional Cardiology publishes regular updates of its recommendations, taking into consideration the most recent clinical evidence. The present update to the 2011 and 2013 CCS APT guidelines incorporates new evidence on how to optimize APT use, particularly in situations where little to no data were previously available. The recommendations update focuses on the following primary topics: 1. The dura...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research